The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Survival outcome of early versus delayed bevacizumab treatment in patients with recurrent glioblastoma.
Mohamed Ali Hamza
No relevant relationships to disclose
Jacob Mandel
No relevant relationships to disclose
Charles A. Conrad
No relevant relationships to disclose
Mark R. Gilbert
Consultant or Advisory Role - EMD Serono; Genentech; Merck; Novartis
Honoraria - EMD Serono; Genentech; Merck; Novartis
Research Funding - Genentech; GlaxoSmithKline; Merck
W. K. Alfred Yung
Consultant or Advisory Role - Actelion; Merck; Novartis
Honoraria - Actelion; Merck; Novartis
Research Funding - Daiichi Sankyo; Novartis
Vinay K. Puduvalli
Consultant or Advisory Role - Novartis
Honoraria - Genentech; Novartis
Research Funding - Celgene; Genentech; Merck; Pfizer
John Frederick De Groot
Consultant or Advisory Role - Genentech; VBL Therapeutics
Honoraria - Merck
Research Funding - AstraZeneca; EMD Serono; Sanofi